Bruce Leuchter, CEO, Neurvati, discusses why patient engagement is essential to understanding rare diseases and driving the ...

The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient ...

As drug development increasingly targets multiple indications, pharma companies must make strategic branding ...

In the final part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, predicts ...

Bruce Leuchter, CEO, Neurvati, discusses the vital role of public participation in healthcare policy, highlighting how ...

State Medicaid leaders create a plan to ensure safety, affordability, and equitable access for children and families living with rare diseases.

In response to the rising importance of real-world evidence (RWE) in showing value to payers beyond traditional clinical ...

In the fourth part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, explains ...

In the second part of this roundtable discussion, a panel of key opinion leaders dive into the key risk factors impacting the pharma manufacturing space, and how the industry should aim to address ...

Dipanwita Das, CEO and co-founder of Sorcero, chats with Pharma Commerce to dig into the evolving drug development landscape, ...

Analysis compares care quality and efficiency within physician groups that treat Medicare Advantage patients under at-risk ...

In the third part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, describes ...